This video via ASCO Post is sourced from ASCO’s 50th Annual Meeting in Chicago.
In this clip:
‘Dr. Jim Armitage, of the University of Nebraska Medical Center, speaks with Michael Pfreundschuh, of the Universitaetsklinikum des Saarlandes in Homburg, Germany about research presented at ASCO’s 50th Annual Meeting by the German High-Grade Lymphoma Study Group. In particular, Drs. Armitage and Pfreundschuh discuss the results of the phase II SEXIE-R-CHOP-14 trial in which researches found that increasing the dose of rituximab by one-third, from 375 mg/m2 to 500 mg/m2, eliminated any gender-related differences in survival outcomes among elderly patients with aggressive CD20+ B-cell lymphomas.’
‘ASCO’ the American Society of Clinical Oncology does great work… here’s just one example.
The State of Cancer Care in America
From the report:
The State of Cancer Care in America: 2014 report—released by the American Society of Clinical Oncology (ASCO) and published by the Journal of Oncology Practice here—is the first-ever, comprehensive look at demographic, economic, and oncology practice trends that will impact cancer care in the United States over the coming years.
With recommendations for addressing the cancer care delivery system’s most pressing concerns, this landmark ASCO report also examines the rapid expansion of health information technology and the growing emphasis on quality measurement and value.
ASCO developed the State of Cancer Care in America: 2014report to help cancer care providers, policy makers, and others more effectively shape the future of cancer care during these uncertain times. The Society will issue annual updates that will track trends and identify emerging issues.
Notes: The American Society of Clinical Oncology has released its first ever report on the State of Cancer Care in America. Peter Yu, MD, FASCO, discusses the report’s findings. Go here to learn more and follow ASCO on twitter via @asco.
Treatment of estrogen receptor (ER)-positive breast cancer can be complicated and depends on many factors, such as disease burden and the duration of a patient’s disease-free interval from the original diagnosis.
For example, a patient with lymph node soft tissue, such as pleural or bone metastatic disease, would be treated differently than a patient with highly proliferative, liver-predominant, extensive visceral disease.
Joanne Blum, MD, notes that the patient in the latter scenario who is symptomatic would receive chemotherapy up front to control the extensive burden of disease, usually with 2 agents to achieve a rapid response.